CA9 and neoplasm: Carbonic anhydrase IX (CAIX)-targeted PET/CT enables the biologically specific visualisation of clear-cell RCC, achieving sensitivities and specificities in the range of 85-90% in prospective phase II and III trials for primary tumour characterisation.